CING

Healthcare Biotechnology

Cingulate Inc.

$4.76

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

69.22M

Avg Volume

157,229

EPS

-$3.51

52W High

$11.89

52W Low

$3.16

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-5.41

P/B Ratio

2.82

EV/EBITDA

-1.93

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(198.7%)

Return on Assets

(66.9%)

Liquidity & Leverage

Current Ratio

3.50

Quick Ratio

3.30

Debt / Equity

0.27

Total Cash

28.40M

Total Debt

6.29M

About

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.